Mariusz Kwiatkowski
Koszalin, ZP, Poland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Primary results from EL1SSAR, a prospective phase IIIb study of first-line atezolizumab plus nab-paclitaxel therapy for patients with PD-L1-positive advanced triple-negative breast cancer.
Journal: Breast (Edinburgh, Scotland)
Published: March 11, 2026
Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 phase III study.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: September 05, 2025
Nivolumab plus ipilimumab for chemotherapy-refractory metastatic castration-resistant prostate cancer: results from the randomized portion of the phase 2 CheckMate 650 trial.
Journal: Nature communications
Published: July 25, 2025
Vibostolimab Coformulated with Pembrolizumab in Participants with Docetaxel-pretreated Metastatic Castration-resistant Prostate Cancer: KEYNOTE-365 Cohort G.
Journal: European urology focus
Published: April 17, 2025
Pembrolizumab plus enzalutamide and androgen deprivation therapy versus placebo plus enzalutamide and androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: the randomized, double-blind, phase III KEYNOTE-991 study.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: January 23, 2025
Pembrolizumab plus enzalutamide versus placebo plus enzalutamide for chemotherapy-naive metastatic castration-resistant prostate cancer: the randomized, double-blind, phase III KEYNOTE-641 study.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: January 23, 2025
KEYSTEP-008: phase II trial of pembrolizumab-based combination in MSI-H/dMMR metastatic colorectal cancer.
Journal: Future oncology (London, England)
Published: September 13, 2023
Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial.
Journal: The Lancet. Oncology
Published: February 23, 2023
KEYNOTE-991: pembrolizumab plus enzalutamide and androgen deprivation for metastatic hormone-sensitive prostate cancer.
Journal: Future oncology (London, England)
Published: January 27, 2023
Showing 1-11 of 11
Last Updated: 09/26/2026